AstraZeneca (AZN) Expected to Announce Quarterly Earnings on Friday

AstraZeneca (NYSE:AZN) is anticipated to post its Q3 2026 results before the market opens on Friday, October 30th. Analysts expect AstraZeneca to announce earnings of $2.60 per share and revenue of $16.00 billion for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Friday, October 30, 2026 at 10:30 AM ET.

AstraZeneca (NYSE:AZN) last announced its quarterly earnings results on Monday, July 27th. The company reported $2.63 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.13. AstraZeneca had a return on equity of 31.45% and a net margin of 17.02%. The firm had revenue of $15.38 billion for the quarter, compared to analysts’ expectations of $15.44 billion. During the same period in the prior year, the business posted $2.17 earnings per share. The company’s revenue was up 6.4% on a year-over-year basis. On average, analysts expect AstraZeneca to post $10.23 EPS for the current fiscal year and $11.37 EPS for the next fiscal year.

AstraZeneca Stock Performance

NYSE AZN opened at $169.36 on Thursday. The company’s 50 day simple moving average is $163.86 and its two-hundred day simple moving average is $180.29. The stock has a market capitalization of $262.66 billion, a PE ratio of 25.32, a P/E/G ratio of 1.33 and a beta of 0.27. The company has a debt-to-equity ratio of 0.47, a current ratio of 0.89 and a quick ratio of 0.67. AstraZeneca has a 1 year low of $153.41 and a 1 year high of $212.71.

Analyst Upgrades and Downgrades

AZN has been the subject of several research analyst reports. Weiss Ratings raised AstraZeneca from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Monday. The Goldman Sachs Group restated a “buy” rating on shares of AstraZeneca in a research note on Wednesday, July 1st. Citigroup reissued a “buy” rating on shares of AstraZeneca in a report on Tuesday, October 6th. CICC Research began coverage on AstraZeneca in a report on Sunday, August 23rd. They issued an “outperform” rating and a $198.00 price objective on the stock. Finally, Zacks Research raised AstraZeneca from a “strong sell” rating to a “hold” rating in a research note on Tuesday, October 13th. Sixteen investment analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $206.67.

About AstraZeneca

AstraZeneca plc is a global, science-led biopharmaceutical company headquartered in Cambridge, United Kingdom. The company discovers, develops and commercializes prescription medicines, with a focus on oncology, biopharmaceuticals and rare diseases. Its research and commercial operations serve patients and healthcare systems across more than 100 countries.

AstraZeneca’s portfolio includes medicines for cancer, respiratory and immune-mediated conditions, cardiovascular, renal and metabolic diseases, and rare disorders.